# US 2021/0280319 A1 · Neuromodulation based adaptive controller for mitral stenosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0280319 A1
- Document ID: US20210280319A1
- Status: Published application
- Kind: A1
- Application number: 17/149,059
- Filed: 2021-01-14
- Published: 2021-09-09
- Earliest claimed: 2020-01-29
- Assignees: Tata Consultancy Services Limited
- Applicants: Tata Consultancy Services Limited
- Inventors: Dibyendu ROY; Oishee MAZUMDER; Aniruddha SINHA; Sundeep KHANDELWAL
- Web page: https://patentgrep.com/patent/US20210280319A1

## CPC

- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/50: for simulation or modelling of medical disorders
- A61B 5/02028: {Determining haemodynamic parameters not otherwise provided for, e.g. cardiac contractility or left ventricular ejection fraction}
- A61B 5/021: Measuring pressure in heart or blood vessels
- G16H 20/30: relating to physical therapies or activities, e.g. physiotherapy, acupressure or exercising
- G16H 40/67: for remote operation
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- G16H 70/60: relating to pathologies
- A61N 1/36114: {Cardiac control, e.g. by vagal stimulation (stimulating the heart A61N1/362)}
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

This disclosure provides a simulation platform to study and perform predictive analysis on valvular heart disease, Mitral stenosis (MS) and provides a control approach to correct hemodynamic imbalances during MS conditions. Conventional approaches of valve repair or replacement are often associated with risk of thromboembolism, need for anticoagulation, prosthetic endocarditis, and impaired left ventricle function. The cardiovascular hemodynamics model of the present disclosure helps to create ‘what if’ conditions to study variations in different hemodynamic parameters like blood flow, aortic and ventricular pressure, etc. during normal and pathological conditions. An adaptive control system in conjunction with the hemodynamic cardiovascular system (CVS) is provided to handle hemodynamic disbalance during moderate to severe MS conditions. The adaptive controller is hypothesized in line with the neuromodulation approach and modulates left ventricular contractility and vagal tone to counter the symptoms associated with MS.

## Claims

### Claim 1

A processor implemented method for enhancing cardiac output (CO) in a subject having Mitral Stenosis (MS), the method comprising the steps of:
receiving, via one or more hardware processors serving as a first controller, an error e1 between an actual left ventricular pressure Plv from a hemodynamic cardiovascular system (CVS) model representative of the subject having MS and a desired left ventricular pressure Plvd, wherein the desired left ventricular pressure corresponds to a healthy cardiovascular system;
generating an updated left ventricle end diastolic compliance {tilde over (c)}lv,d via the first controller, by minimizing the error e1;
receiving, via one or more hardware processors serving as a second controller, an error e2 between an actual aortic pressure Psa from the hemodynamic CVS model and a desired aortic pressure Psad, wherein the desired aortic pressure corresponds to the healthy cardiovascular system;
generating an updated systemic vascular resistance {tilde over (R)}s, via the second controller, by minimizing the error e2;
receiving, via one or more hardware processors serving as a third controller, the updated left ventricle end diastolic compliance {tilde over (c)}lv,d and the updated systemic vascular resistance {tilde over (R)}s to generate control inputs u1 and u2 for opening and closing a mitral valve and an aortic valve respectively; and
receiving, via the hemodynamic CVS model, the updated left ventricle end diastolic compliance {tilde over (c)}lv,d, the updated systemic vascular resistance {tilde over (R)}s and the generated control inputs u1 and u2; wherein the {tilde over (c)}lv,d and the {tilde over (R)}s represent parameters that are adaptively controlled by neuromodulation for enhancing the CO in the subject having MS.

### Claim 2 (depends on 1)

The processor implemented method of claim 1, wherein the updated left ventricle end diastolic compliance {tilde over (c)}lv,d is based on the actual left ventricular pressure Plv, a rate of change of the desired left ventricular pressure {dot over (P)}lvd and a diastolic time duration T−Ts, and wherein T represents duration of a cardiac cycle having a systolic duration Ts, such that the {tilde over (c)}lv,d is limited to a physiological acceptable range for left ventricle end diastolic compliance [clv,dmin,clv,dmax].

### Claim 3 (depends on 2)

The processor implemented method of claim 2, wherein the updated left ventricle end diastolic compliance {tilde over (c)}lv,d is represented according to the equation
c
~
l
⁢
ν
,
d
=
{
c
lν
,
d
max
⁢
⁢
if
⁢
⁢
c
^
lv
,
d
>
c
lv
,
d
max
c
^
lv
,
d
⁢
⁢
if
⁢
⁢
c
lv
,
d
max
≥
c
^
lv
,
d
≥
c
lv
,
d
min
,
c
lv
,
d
min
⁢
⁢
if
⁢
⁢
c
^
lv
,
d
<
c
lv
,
d
min
and wherein ĉlv,d is an estimated left ventricle end diastolic compliance and is represented according to the equation
c
^
lv
,
d
=
exp
(
-
P
.
lv
d
⁡
(
T
-
T
s
)
P
lv
)
.

### Claim 4 (depends on 1)

The processor implemented method of claim 1, wherein the updated systemic vascular resistance {tilde over (R)}s is based on the actual aortic pressure Psa, a rate of change of the desired aortic pressure {dot over (P)}sad and a left atrial pressure Pla, such that the {tilde over (R)}s is limited to a physiological acceptable range for systemic vascular resistance [Rsmin,Rsmax].

### Claim 5 (depends on 4)

The processor implemented method of claim 4, wherein the updated systemic vascular resistance {tilde over (R)}s is represented according to the equation
R
˜
s
=
{
R
s
max
⁢
⁢
if
⁢
⁢
R
^
s
>
R
s
max
R
^
s
⁢
⁢
if
⁢
⁢
R
s
max
≥
R
^
s
⁢
≥
R
s
min
,
R
s
min
⁢
⁢
if
⁢
⁢
R
^
s
<
R
s
min
wherein {circumflex over (R)}s is an estimated systemic vascular resistance and is represented according to the equation
R
˜
s
=
-
P
s
⁢
a
-
P
la
c
sa
⁢
P
.
s
⁢
a
d
,
and wherein csa is a constant representing a systemic vascular compliance.

### Claim 6 (depends on 1)

The processor implemented method of claim 1, wherein a cascaded control unit ũ based on the control inputs u1 and u2 is provided to the hemodynamic CVS model, wherein the cascaded control unit ũ is represented in a state space form according to the equation ũ={tilde over (G)}−1({dot over (x)}d−Ãx)|Rs={tilde over (R)}s,clv,d={tilde over (c)}lv,d, and wherein {dot over (x)}=A(t)x+G(x,t)u,
x=[Plv Pla Psa]T, Pla representing a left atrial pressure,
u=[u1 u2]T,
A(t) is a state matrix represented as
[
-
c
.
lv
⁡
(
t
)
c
lv
⁡
(
t
)
0
0
0
-
c
.
la
⁡
(
t
)
c
la
⁡
(
t
)
1
c
la
⁡
(
t
)
⁢
R
s
0
1
c
sa
⁢
R
s
-
1
c
sa
⁢
R
s
]
,
G(x,t) is an input matrix represented as
[
P
la
-
P
lv
c
lv
⁡
(
t
)
⁢
R
mi
-
P
lv
-
P
sa
c
lv
⁡
(
t
)
⁢
R
a
⁢
⁢
o
-
P
la
-
P
lv
c
la
⁡
(
t
)
⁢
R
mi
0
0
P
lv
-
P
sa
c
sa
⁢
R
ao
]
,
xd(t)=[Plvd Plad Psad]T represents a desired state corresponding to the healthy cardiovascular system,
Ã(t)=A(t)|{tilde over (R)}s,{tilde over (c)}lv,d, and
{tilde over (G)}(x,t)=G(x,t)|{tilde over (c)}lv,d.

### Claim 7

A system for enhancing cardiac output (CO) in a subject having Mitral Stenosis (MS), the system comprising:
one or more data storage devices operatively coupled to one or more hardware processors and configured to store instructions configured for execution via the one or more hardware processors serving as a first controller, a second controller, a third controller and a hemodynamic cardiovascular system (CVS) model representative of the subject having MS to:
receive via the first controller, an error e1 between an actual left ventricular pressure Plv from the hemodynamic CVS model and a desired left ventricular pressure Plvd, wherein the desired left ventricular pressure corresponds to a healthy cardiovascular system;
generate an updated left ventricle end diastolic compliance {tilde over (c)}lv,d via the first controller, by minimizing the error e1;
receive via the second controller, an error e2 between an actual aortic pressure Psa from the hemodynamic CVS model and a desired aortic pressure Psad, wherein the desired aortic pressure corresponds to the healthy cardiovascular system;
generate an updated systemic vascular resistance {tilde over (R)}s, via the second controller, by minimizing the error e2;
receive, via the third controller, the updated left ventricle end diastolic compliance {tilde over (c)}lv,d and the updated systemic vascular resistance {tilde over (R)}s to generate control inputs u1 and u2 for opening and closing a mitral valve and an aortic valve respectively; and
receive, via the hemodynamic CVS model, the updated left ventricle end diastolic compliance {tilde over (c)}lv,d, the updated systemic vascular resistance {tilde over (R)}s and the generated control inputs u1 and u2; wherein the {tilde over (c)}lv,d and the {tilde over (R)}s represent parameters that are adaptively controlled by neuromodulation for enhancing the CO in the subject having MS.

### Claim 8 (depends on 7)

The system of claim 7, wherein the updated left ventricle end diastolic compliance {tilde over (c)}lv,d is based on the actual left ventricular pressure Plv, a rate of change of the desired left ventricular pressure {dot over (P)}lvd and a diastolic time duration T−Ts, and wherein T represents duration of a cardiac cycle having a systolic duration Ts, such that the {tilde over (c)}lv,d is limited to a physiological acceptable range for left ventricle end diastolic compliance [clv,dmin,clv,dmax].

### Claim 9 (depends on 8)

The system of claim 8, wherein the updated left ventricle end diastolic compliance {tilde over (c)}lv,d is represented according to the equation
c
~
l
⁢
ν
,
d
=
{
c
lν
,
d
max
⁢
⁢
if
⁢
⁢
c
^
lv
,
d
>
c
lv
,
d
max
c
^
lv
,
d
⁢
⁢
if
⁢
⁢
c
lv
,
d
max
≥
c
^
lv
,
d
≥
c
lv
,
d
min
,
c
lv
,
d
min
⁢
⁢
if
⁢
⁢
c
^
lv
,
d
<
c
lv
,
d
min
and wherein ĉlv,d is an estimated left ventricle end diastolic compliance and is represented according to the equation
c
^
lv
,
d
=
exp
(
-
P
.
lv
d
⁡
(
T
-
T
s
)
P
lv
)
.

### Claim 10 (depends on 7)

The system of claim 7, wherein the updated systemic vascular resistance {tilde over (R)}s is based on the actual aortic pressure Psa, a rate of change of the desired aortic pressure {dot over (P)}sad and a left atrial pressure Pla, such that the {tilde over (R)}s is limited to a physiological acceptable range for systemic vascular resistance [Rsmin,Rsmax].

### Claim 11 (depends on 10)

The system of claim 10, wherein the wherein the updated systemic vascular resistance {tilde over (R)}s is represented according to the equation {tilde over (R)}s=
{
R
s
max
⁢
⁢
if
⁢
⁢
R
^
s
>
R
s
max
R
^
s
⁢
⁢
if
⁢
⁢
R
s
max
≥
R
^
s
⁢
≥
R
s
min
,
R
s
min
⁢
⁢
if
⁢
⁢
R
^
s
<
R
s
min
wherein {circumflex over (R)}s is an estimated systemic vascular resistance and is represented according to the equation
R
^
s
=
-
P
s
⁢
a
-
P
la
c
sa
⁢
P
.
s
⁢
a
d
,
and wherein csa is a constant representing a systemic vascular compliance.

### Claim 12 (depends on 7)

The system of claim 7, wherein the hemodynamic CVS model is further configured to receive a cascaded control unit ũ based on the control inputs u1 and u2, wherein the cascaded control unit ũ is represented in a state space form according to the equation ũ={tilde over (G)}−1({dot over (x)}d−Ãx)|Rs={tilde over (R)}s,clv,d={tilde over (c)}lv,d, and wherein {dot over (x)}=A(t)x+G(x,t)u,
x=[Plv Pla Psa]T, Pla representing a left atrial pressure,
u=[u1 u2]T,
A(t) is a state matrix represented as
[
-
c
.
lv
⁡
(
t
)
c
lv
⁡
(
t
)
0
0
0
-
c
.
la
⁡
(
t
)
c
la
⁡
(
t
)
1
c
la
⁡
(
t
)
⁢
R
s
0
1
c
sa
⁢
R
s
-
1
c
sa
⁢
R
s
]
,
G(x,t) is an input matrix represented as
[
P
la
-
P
lv
c
lv
⁡
(
t
)
⁢
R
mi
-
P
lv
-
P
sa
c
lv
⁡
(
t
)
⁢
R
a
⁢
⁢
o
-
P
la
-
P
lv
c
la
⁡
(
t
)
⁢
R
mi
0
0
P
lv
-
P
sa
c
sa
⁢
R
ao
]
,
xd(t)=[Plvd Plad Psad]T represents a desired state corresponding to the healthy cardiovascular system,
Ã(t)=A(t)|{tilde over (R)}s,{tilde over (c)}lv,d, and
{tilde over (G)}(x,t)=G(x,t)|{tilde over (c)}lv,d.

### Claim 13

A computer program product comprising a non-transitory computer readable medium having a computer readable program embodied therein, wherein the computer readable program, when executed on a computing device, causes the computing device to:
receive, via one or more hardware processors serving as a first controller, an error e1 between an actual left ventricular pressure Plv from a hemodynamic cardiovascular system (CVS) model representative of the subject having MS and a desired left ventricular pressure Plvd, wherein the desired left ventricular pressure corresponds to a healthy cardiovascular system;
generate an updated left ventricle end diastolic compliance {tilde over (c)}lv,d via the first controller, by minimizing the error e1;
receive, via one or more hardware processors serving as a second controller, an error e2 between an actual aortic pressure Psa from the hemodynamic CVS model and a desired aortic pressure Psad, wherein the desired aortic pressure corresponds to the healthy cardiovascular system;
generate an updated systemic vascular resistance {tilde over (R)}s, via the second controller, by minimizing the error e2;
receive, via one or more hardware processors serving as a third controller, the updated left ventricle end diastolic compliance {tilde over (c)}lv,d and the updated systemic vascular resistance {tilde over (R)}s to generate control inputs u1 and u2 for opening and closing a mitral valve and an aortic valve respectively; and
receive, via the hemodynamic CVS model, the updated left ventricle end diastolic compliance {tilde over (c)}lv,d, the updated systemic vascular resistance {tilde over (R)}s and the generated control inputs u1 and u2; wherein the {tilde over (c)}lv,d and the {tilde over (R)}s represent parameters that are adaptively controlled by neuromodulation for enhancing the CO in the subject having MS.
